ATE361071T1 - Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie - Google Patents

Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie

Info

Publication number
ATE361071T1
ATE361071T1 AT02785535T AT02785535T ATE361071T1 AT E361071 T1 ATE361071 T1 AT E361071T1 AT 02785535 T AT02785535 T AT 02785535T AT 02785535 T AT02785535 T AT 02785535T AT E361071 T1 ATE361071 T1 AT E361071T1
Authority
AT
Austria
Prior art keywords
irbesartan
prevent
pulmonary hypertension
treat pulmonary
hypertension
Prior art date
Application number
AT02785535T
Other languages
English (en)
Inventor
Sylvie Cosnier-Pucheu
Dino Nisato
Alain Roccon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of ATE361071T1 publication Critical patent/ATE361071T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
AT02785535T 2001-10-26 2002-10-09 Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie ATE361071T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0113936A FR2831446B1 (fr) 2001-10-26 2001-10-26 Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire

Publications (1)

Publication Number Publication Date
ATE361071T1 true ATE361071T1 (de) 2007-05-15

Family

ID=8868812

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02785535T ATE361071T1 (de) 2001-10-26 2002-10-09 Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie

Country Status (24)

Country Link
US (2) US20040242567A1 (de)
EP (1) EP1441723B1 (de)
JP (1) JP4542777B2 (de)
CN (1) CN100418526C (de)
AT (1) ATE361071T1 (de)
AU (1) AU2002350832B2 (de)
BR (1) BR0213479A (de)
CA (1) CA2461625C (de)
CY (1) CY1106746T1 (de)
DE (1) DE60219940T2 (de)
DK (1) DK1441723T3 (de)
EA (1) EA007952B1 (de)
ES (1) ES2286304T3 (de)
FR (1) FR2831446B1 (de)
HU (1) HUP0401633A3 (de)
IL (2) IL161116A0 (de)
IS (1) IS2849B (de)
MX (1) MXPA04003910A (de)
NO (1) NO332313B1 (de)
NZ (1) NZ532130A (de)
PL (1) PL209263B1 (de)
PT (1) PT1441723E (de)
WO (1) WO2003035062A1 (de)
ZA (1) ZA200402696B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US7811606B2 (en) 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
TR200301553A1 (tr) * 2003-09-18 2005-10-21 Nobel �La� Sanay�� Ve T�Caret A.�. İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006067601A1 (en) * 2004-12-23 2006-06-29 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of irbesartan and hydrochlorothiazide and processes for their preparation
CN100367959C (zh) * 2006-08-29 2008-02-13 陈俊云 一种含有依贝沙坦的药物
GB0617171D0 (en) * 2006-08-31 2006-10-11 Generics Uk Ltd Novel compositions and methods
JP2024510446A (ja) * 2021-03-23 2024-03-07 ダイメリックス バイオサイエンス ピーティーワイ リミテッド 炎症性疾患の処置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
NZ237476A (en) * 1990-03-20 1994-01-26 Sanofi Sa N-substituted heterocyclic compounds and pharmaceutical compositions.
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
EP1106210A3 (de) 1999-12-07 2003-12-03 Pfizer Products Inc. Zusammensetzungen, für die Behandlung von diabetischen Komplikationen, welche Aldosereductasehemmern und antihypertensive Mitteln enthalten

Also Published As

Publication number Publication date
MXPA04003910A (es) 2004-07-23
JP4542777B2 (ja) 2010-09-15
PT1441723E (pt) 2007-07-26
US20040242567A1 (en) 2004-12-02
EA007952B1 (ru) 2007-02-27
FR2831446B1 (fr) 2004-03-05
CA2461625A1 (en) 2003-05-01
IL161116A (en) 2010-12-30
PL368737A1 (en) 2005-04-04
AU2002350832B2 (en) 2006-11-30
NO20041732L (no) 2004-07-23
EP1441723B1 (de) 2007-05-02
US8088827B2 (en) 2012-01-03
EP1441723A1 (de) 2004-08-04
CN100418526C (zh) 2008-09-17
ES2286304T3 (es) 2007-12-01
DE60219940D1 (de) 2007-06-14
DE60219940T2 (de) 2008-01-17
CY1106746T1 (el) 2012-05-23
NO332313B1 (no) 2012-08-27
FR2831446A1 (fr) 2003-05-02
NZ532130A (en) 2006-10-27
DK1441723T3 (da) 2007-09-10
EA200400438A1 (ru) 2004-10-28
US20090247510A1 (en) 2009-10-01
JP2005506369A (ja) 2005-03-03
PL209263B1 (pl) 2011-08-31
CN1610548A (zh) 2005-04-27
BR0213479A (pt) 2004-11-03
WO2003035062A1 (fr) 2003-05-01
HUP0401633A2 (hu) 2004-12-28
IS7200A (is) 2004-03-29
HUP0401633A3 (en) 2009-06-29
IL161116A0 (en) 2004-08-31
IS2849B (is) 2013-09-15
ZA200402696B (en) 2005-06-29
CA2461625C (en) 2011-07-05

Similar Documents

Publication Publication Date Title
ATE492542T1 (de) Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
ATE337780T1 (de) Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns
ATE336996T1 (de) Verwendung von flavonoid-derivaten zur behandlung von atopischem ekzem
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE525073T1 (de) Verwendung von pyrimidylaminobenzamiden zur behandlung von durch modulation einer tie-2 kinase-aktivität verursachten krankheiten
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE410235T1 (de) Behandlung von ballastwasser
DE602005014632D1 (de) Pyrrol- bzw. imidazolamide zur behandlung von obesitas
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60329326D1 (de) Tace inhibitoren
DE60213365D1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
ATE320255T1 (de) Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen
ATE337004T1 (de) Verwendung von mangafodipir zur behandlung der hepatozellularen insuffizienz
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE359088T1 (de) Verwendung von interleukin-18 zur behandlung von uv-assoziierten hautkrankheiten
ATE476185T1 (de) Verwendung von ciclesonid zur behandlung von entzündlichen darmerkrankungen
ATE308321T1 (de) Verwendung von c2-substituierten indan-1-ol- systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas
DE60321377D1 (de) Verwendung von levocetirizin zur behandlung von persistierender allergischer rhinitis
DE60215203D1 (de) VERWENDUNG VON AMINOMETHYL CHROMANEN ZUR BEHANDLUNG DER NEBENWIRKUNGEN VON NEUROLEPTIkA
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1441723

Country of ref document: EP